SEMPRA - EQUITY AND EARNINGS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2026

The table below presents preferred stock outstanding at SoCalGas:


PREFERRED STOCK OUTSTANDING
(Dollars in millions, except per share amounts)
	December 31, 2025
$25 par value, authorized 1,000,000 shares:
6% Series, 79,011 shares outstanding	$	3
6% Series A, 783,032 shares outstanding	19
SoCalGas - Total preferred stock	22
Less: 50,970 shares of the 6% Series outstanding owned by Pacific Enterprises	(2)
Sempra - Total preferred stock of subsidiary	$	20

Schedule Of Sale Of Stock

The principal terms of these forward sale agreements at September 30, 2026 are as follows:

FORWARD SALE AGREEMENTS UNDER THE ATM PROGRAM THAT REMAIN SUBJECT TO FUTURE SETTLEMENT

(Dollars in millions, except per share amounts)

Date of agreement

Number of shares subject to agreement

Number of shares that remain to be settled

Initial forward price per share

Expected net proceeds(1)

Forward purchaser

Sales commissions

Final settlement date

November 18, 2024

2,909,274

$92.1546

$268

Bank of America, N.A.

$2.4

December 31, 2027

February 26, 2025

2,087,317

$70.6593

$147

Wells Fargo Bank, N.A.

$1.3

March 31, 2027

(1) Expected net proceeds assumes full physical settlement, is net of sales commission but does not deduct other equity issuance costs, and is subject to certain adjustments pursuant to the applicable forward sale agreement.

Schedule Of Transfers (To) From Noncontrolling Interest

The following table summarizes net income attributable to Sempra and transfers (to) from CRNCI and NCI, which shows the effects of changes in Sempra’s ownership interest in its subsidiaries on Sempra’s shareholders’ equity.


NET INCOME ATTRIBUTABLE TO SEMPRA AND TRANSFERS (TO) FROM CRNCI AND NCI
(Dollars in millions)
	Three months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025
Sempra:
Net income attributable to Sempra	$	883	$	95	$	2,717	$	1,485
Transfers (to) from CRNCI and NCI:
Increase in shareholders’ equity from investor equity subscription	—		16		—		16
(Decrease) increase in shareholders’ equity from allocation of interests(1)	(42)		635		(56)		635
Net transfers (to) from CRNCI and NCI	(42)		651		(56)		651
Change from net income attributable to Sempra and transfers (to) from CRNCI and NCI	$	841	$	746	$	2,661	$	2,136

(1) We describe the allocation of interests in Note 10.

Schedule of Earnings Per Share, Basic and Diluted


EARNINGS PER COMMON SHARE COMPUTATIONS
(Dollars in millions, except per share amounts; shares in thousands)
	Three months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025
Sempra:
Numerator:
Earnings attributable to common shares	$	877	$	77	$	2,710	$	1,444

Denominator:
Weighted-average common shares outstanding for basic EPS(1)	654,262		652,948		653,966		652,538
Dilutive effect of common shares sold forward	396		267		465		123
Dilutive effect of stock options and RSUs(2)	1,281		794		1,362		759
Weighted-average common shares outstanding for diluted EPS	655,939		654,009		655,793		653,420

EPS:
Basic	$	1.34	$	0.12	$	4.14	$	2.21
Diluted	$	1.34	$	0.12	$	4.13	$	2.21

(1) Includes 368 and 492 fully vested RSUs held in our deferred compensation plan in the three months ended September 30, 2026 and 2025, respectively, and 373 and 502 of such RSUs in the nine months ended September 30, 2026 and 2025, respectively. These fully vested RSUs are included in weighted-average common shares outstanding for basic EPS because there are no conditions under which the corresponding shares will not be issued.

(2) Due to market fluctuations of both Sempra common stock and the comparative indices used to determine the vesting percentage of our total shareholder return performance-based RSUs, which we discuss in Note 14 of the Notes to Consolidated Financial Statements in the Annual Report, dilutive RSUs may vary widely from period-to-period.